Try our Advanced Search for more refined results
Life Sciences - March, 2016
392 articles
- FTC Puts No-Authorized-Generic Pharma Deals In Crosshairs
- 3 Takeaways From FDA's Biosimilar Labeling Guidance
- Fired J&J Exec's Secret Romance Recalled By Witness
- Criminal Case Halts USPLabs Coverage Fight, Magistrate Says
- BMS Cancer Treatment Patent Survives Merck Attack, For Now
- Pa. Judge Limits Mom's Testimony In Paxil Birth Defect Trial
- Rising Star: Hogan Lovells' Adam Bellack
- Deals Rumor Mill: Medivation, Giordano's, SendGrid
- IRS Drops $119M Tax Bill To Carmex Fortune's Heirs
- GSK To Ease Access To Generic Drugs In Developing Countries
- Fed. Circ. Won't Rehear Case Over ITC's Digital Power
- Busy 1st Quarter For FCPA Enforcement
- Law And Regulation Of 3-D Printed Medical Devices
- FTC Sues Endo, Generics For Pay-For-Delay Agreements
- Shifting The Law Firm Business Development Paradigm
- Gilead Says Atty's Lie Kills Merck IP Behind $200M Jury Win
- Tyco Wants Directed Verdict In Insurer's $60M Heist Suit
- New FDA Rules Ease Access To Abortion Drug
- Pfizer, Allergan Say FTC Seeking More Info On Inversion Deal
- House Panel Subpoenas Fetal Tissue Research Cos.
- Valeant Seeks Breathing Room From Lenders
- Law360 Names Top Attorneys Under 40
- Houston IP Attorney Duo Leaves Baker Botts For Reed Smith
- FDA Approves Zika Test For Blood Donations
- SEC Fines, Bans Biotech Venture Capitalist Over $18M Fraud
- Sensus Healthcare Delays $20M IPO Amid Slumping Market
- How Biotechs Survive Despite Volatile Capital Markets
- How Employers Can Successfully Challenge Agency Guidance
- AbbVie Escapes Shire Investors' Suit Over Failed Merger
- Gilead Slams Merck's Bid To Boost $200M Award In IP Row
- USPTO Added Too Little Time To Supernus Patent, Suit Says
- Aveo Pays $4M To End SEC Claims It Misled Investors
- Arrowhead Ducks Investor Suit Over Hep B Drug Trial
- Feds Still Investigating Whether Biomet Broke Rules Abroad
- FDA Warning Wire: 'Virulent Pathogens' In Fancy Soaps
- Warner Says Mylan Misstatements Key To Doryx Antitrust Row
- Indivior Keeps Fighting For Resale Docs In Antitrust Case
- CIT Takes 3rd Option To Classify Imports Of Krill Oil
- Cancer-Focused Biotech Aeglea Sets Terms On $60M IPO
- Pharma Groups Back Pfizer In 3rd Circ. Pay-For-Delay Case
- TC Heartland's Restraints On ANDA Litigation Jurisdiction
- NJ Appeals Panel Affirms $11M J&J Pelvic Mesh Judgment
- Pure Green Coffee Firms Drained Of Weight Loss Claims
- New FDA Rules Put Onus On Doctors To Curb Opioid Abuse
- Affymetrix Says Thermo Fisher Deal Still Beats Ex-Execs'
- NY Launches E-Prescribing In Attempt To Curb Opioid Abuse
- Merck Seeks To Boost $200M Award In Gilead Drug IP Case
- Pediatric Cardiologist Testifies To Paxil-Heart Defect Link
- Allergan Faces NJ Patent Suit Over Generic ADHD Medication
- Supplement Distributor Didn't Lose On Deal, 2nd Circ. Told
- Benicar Maker Says NJ Law Limits Witness Coaching
- Actavis' Generic Lialda Still Too Early, Judge Finds
- Zimmer Replaces 2nd Bellwether Suit Over Knee Implants
- Generic Reglan Users Agree To Drop Amneal Claims In Philly
- Justices Reject P&G's Class Cert. Appeal In 'Snake Oil' Claim
- High Court Won't Hear Daiichi Sankyo's Patent Term Appeal
- Success Of Opioid Addiction Bill Would Rely On Funding
- Why Sanofi Is Required Reading For Securities Attorneys
- Mindless Lawyering: Is Doc Review 'The Practice Of Law'?
- SEC Hits Florida Accounting Firm Over MusclePharm Audit
- Abbott Whistleblower Defends $219M FCA Claim To Jury
- 7th Circ. Wants More Info In Suit Over Ill. Medicaid Drug Cap
- Generic Cos. Face Another Antitrust Suit Over Drug Prices
- Supple False Ad Suit Kept In Fed. Court, Then Nixed
- It's Time To Nix Homeopathic False Ad Claims, Hyland's Says
- Health Hires: New Partners At Proskauer, Perkins Coie
- Express Scripts Says Pharmacies Don't Show Conspiracy
- Stryker Toe Implant Suit Belongs In Fed Court, 5th Circ. Says
- 3 Charged In $1.2M Corporate Embezzlement Scheme
- Health-Focused 1315 Capital Nabs $179.5M Toward Fund
- J&J Unit Seeks Infringement Finding In Testing Strip Row
- Sandoz Shreds AbbVie's 'Misleading' Biosimilar Petition
- Gilead Hit With $200M Verdict In Merck Drug Patent Row
- Merck, Others Beat Eye Drop Dosage Suit For 2nd Time
- Paxil Linked To Heart Defects In Babies, Philly Jury Told
- FDA Floats Rules For Abuse-Deterrent Generic Opioids
- FCA Sampling Gets New Ammo In High Court's Tyson Ruling
- Genzyme Hits Sun With Suit Over Generic Leukemia Drug
- Senate Dems Push Regulators On Pot Biz Banking
- Indivior Says FDA Petition Didn't Delay Generic Suboxone
- Fed. Circ. Upholds Validity Of Depomed Drug Patents
- Commerce Opens New Chinese Refrigerant Compound Probe
- The Future Keeps Happening To Legal Services
- India Won't Cease Controversial Drug-Licensing Policy
- Endeavour Vision Nets $281M For Med-Tech Fund
- Yale To Fight Conn. Proposal To Revoke Tax-Exempt Status
- Frazier Healthcare Nabs $525M For Growth Buyout Fund
- Law360 Reveals 400 Largest US Firms
- Reasonable Royalty Takeaways From Fed. Circ. In 2015
- Shire, Actavis Feud Over Unresolved Issues At Lialda IP Trial
- Pa. Judge Reduces Claims In Essure Injury Suit
- 1st Circ. Affirms Wyeth's Win In Weight-Loss Drug Trial
- Icahn Beats Suits Over Short-Term Trades In Herbalife, Others
- Trial Judge Can't Award Atty Fees During Appeal, Firm Says
- Morgan Lewis Sheds Over 100 Attorneys After Bingham Deal
- 5 Firms On The Rise In 2016
- The Firms That Lost The Most Ground This Year
- Greenberg Traurig On Track To Become Biggest US Firm
- J&J Exec Says Married Doc's Relationship Violated Policy
- Pfizer Says Zoloft Defect Claims Still Suffer Lack Of Science
- Gilead Says Patent, Antitrust Claims Over HIV Drug Fail
- Merck Patent Claims Marred By 'Unclean Hands,' Gilead Says
- State Claims Too Late For GSK, Teva Lamictal Antitrust Row
- PTAB Approves Kyle Bass' 2nd Bid To Review MS Drug Patent
- KaloBios Investors Fight Hogan Lovells' Ch. 11 Fee Request
- Transfer Of Pelvic Mesh MDL Cases Is Premature, Judge Says
- Philly Judge Won't Consolidate Testosterone Cases
- Nicoll Davis Beats DQ Bid In Supplement Co.'s Kickback Row
- Novartis Pays $25M To SEC In Chinese FCPA Case
- Demystifying The Attorney-Client Privilege
- Norton Rose Fulbright Picks Up IP Pro From DLA Piper
- 4th Circ. Reverses Trademark Ruling On Bayer's 'Flanax'
- Philips Unit Pays $35M To Settle Sleep Mask Kickback Claims
- Ex-Warner Chilcott Exec Denied 'Early Preview' Of Trial
- Sidley Austin Hires 3 IP Litigators From Ropes & Gray
- Bristol-Myers To Pay Up To $600M For Autoimmune Biotech
- Correlation Or Cause: Brand-Name Drug Prescription Rates
- The Expansive Impact Of Acorda On Hatch-Waxman Cases
- Relator Nets Another $66M Payday In Novartis Kickback Suit
- Flying Solo: SEC's Growing Independence In FCPA Actions
- 1 Year Later: Omnicare's Effect On Opinion Liability
- Advaxis Must Face Claims Over 'Spring-Loaded' Stock Options
- US, Mexico Interpret NAFTA In Lilly's Canadian Patent Fight
- Merck Drug Patents Asserted Against Gilead Valid, Jury Finds
- Abbott Faces $219M FCA Trial Over Off-Label Stent Marketing
- Mylan Ruling Cements Del., NJ As Top ANDA Venues
- FDA Warning Wire: OTC Drug Dangers, Lead Contamination
- KaloBios Irons Out Issues With $14M Ch. 11 Financing Plan
- Amgen Hedges On Sandoz's High Court Biosimilar Petition
- Ex-Warner Chilcott Exec Asks To Limit Scope At Kickback Trial
- Ex-DLA Piper Product Liability Leader Joins Sidley in NY
- Detecting Marijuana-Impaired Drivers: A Lesson In History
- Actos Buyers Drop Generic Cos. From Pay-For-Delay Appeal
- NJ Pharmacy Pays $1.9M For Alleged Medicaid Overbilling
- Pfizer Urges 3rd Circ. Not To Revive Lipitor Antitrust Row
- Shkreli Judge Stays SEC Case, Offers Quick Criminal Trial
- Trial Pros: Choate Hall's Eric Marandett
- CIT Denies Amicus Bid In Supplement Customs Battle
- FDA Adds Black-Box Warning To Opioids
- FDA Challenges Direct-To-Consumer Genetic Tests
- Patients Target Bayer Over Essure Safety Amid FDA Scrutiny
- Insurer Blames Tyco Security For $60M Eli Lilly Drug Heist
- Sequenom Takes Fetal DNA Patent Row To High Court
- Anthem Hits Express Scripts With $15B Suit Over Pricing
- KaloBios Closer To $14M Ch. 11 Funding Despite Shkreli Ties
- MoFo Lures Ex-Baker Botts ITC Chair In DC
- Endo's Consumer Fraud Claim Tossed In Actavis False Ad Suit
- Frommer Lawrence Nabs Ex-DLA Piper Life Sciences Atty
- Daiichi Urges High Court To Allow Patent Term Extension
- Widow Wants 2nd Chance At Seeger Weiss Over Vioxx Deal
- ARCH Venture Partners Seeks $400M For 9th Fund
- 3rd Circ. Affirms J&J Win In Ex-Worker's Severance Suit
- FDA Eyes Ban On Powdered Medical Gloves
- Valeant Replacing CEO After Stock Drops, Investigations
- Affymetrix Snubs $1.5B Takeover Bid, Prefers Thermo Fisher
- FedEx Gets Drug Trafficking Claims Trimmed After DOJ Flub
- Justices Won't Decide Venue For Patent Interference Appeals
- ConforMIS Moves To Toss Suit Over $140M IPO
- Social Media As A Measure Of Cognitive Ability
- Is Student Loan Stress The New Norm For Law School?
- Olympus: Another Life Sciences Company Gets Hit Hard
- J&J Settling Morcellator Cases, Plaintiffs' Attorney Says
- 7 Best Practices For Managing An Associate's Personal Crisis
- Globus Dodges Subpoena In Doc's Patent Row With Medtronic
- Valeant Not On Verge Of Bankruptcy, CEO Tells Staff
- Insurer Wants Coverage Row Halted Until FCA Suit Ends
- Effexor Settlement No Shield For Antitrust Suit, FTC Says
- Fed. Circ. Affirms Warner Chilcott Atelvia Patents Are Invalid
- Froman Dismisses Notion Of Renegotiating TPP
- The Amarin Win: How Cahill Gordon Took On The FDA
- Senate OKs Prescription Drug Oversight Bill
- Patent Term Extension Considerations For Regulated Products
- Fed. Circ. Sets Wide Jurisdiction Rule In ANDA Patent Cases
- J&J Patients Won $502M Verdict With Rare Scope Of Evidence
- Braintree To Take Battle Over Laxative Patent To Fed. Circ.
- Aventis Escapes Claims That Clomid Warnings Fell Short
- Health Orgs Say Proposed Medicare Reform Will Harm Patients
- Arch Lambastes Eli Lilly's Sanctions Bid As 'Desperation'
- NY Doc Convicted For Role In Massive Oxycodone Pill Ring
- Gore-Tex Maker Says Antics In Stent IP Row Need Sanctions
- 2nd Circ. Tosses Pharma Rep.'s Malicious Prosecution Suit
- Cancer Treater's IPO Nets $102M; Device Maker Reduces Plans
- Endo, AbbVie Back Philly Testosterone Case Consolidation
- Pa. Judge Won't Undo 4th Philly Risperdal Verdict
- Patent Invalidation Need Not Nix Royalties, EU Adviser Says
- CORRECTED: Colorado Atty Accused Of Botching Med Tech Co.'s Patents
- How California Streamlined Costly, Time-Consuming Litigation
- Q&A With Covington & Burling's Marney Cheek
- Mylan Slams Warner's 'Overheated Rhetoric' In Doryx Row
- J&J Hit With $502M Verdict In 2nd Pinnacle Bellwether Trial
- A Historic Low For Drug Promotion Warning Letters
- Rethinking Seagate At The Supreme Court
- Biosimilar Makers Turn To IPRs Despite Mixed Results
- Wealth Management For Senior Partners
- OPINION: Missed Opportunity In Supreme Court Nomination
- Ex-QB Can't Pick Off Supplement False Ad Suit, 9th Circ. Told
- In His Own Words: 4 Key Garland Opinions
- Garland's High Court Nomination Battle Likely To Drag On
- Firm Says It Deserves All Fees From Pfizer's $785M Settlement
- Drug Co., Alaskan AG Drop Actions Against Each Other
- CDC's Opioid Stance Hurts Drug Cos. In Marketing Suits
- Judge Garland Could Bring New Consensus To High Court
- Hernia Mesh Maker Seeks Defense In Trade Secrets Fight
- Attorneys Weigh In On Obama's Supreme Court Pick
- Latham Advises Pet Meds Maker Putney In $200M Dechra Sale
- Amgen Patents For Cholesterol Drug Valid, Jury Finds
- Abbott's Handwritten Accord Is Binding, 7th Circ. Affirms
- FDA Stand On Drug-Combo Exclusivity Was Valid, Judge Says
- Texas Lawyer Accused Of Botching IUD Defect Case
- Shkreli Says Retrophin Must Pick Up $5M Legal Tab
- Fish Oil Class Couldn't Prove Loss, NJ Panel Says
- Vectura Inks $622M Deal For Fellow UK Inhaler Maker
- J&J Baby Sleep Aid False Ad Row Back In NJ State Court
- Q&A With WilmerHale's Rachael Kent
- Calif. Asks Innovator Drug Brands To Do The Impossible
- Real Estate Rumors: Ping An Insurance, Ares, EB-5 Deal
- Obama Picks Garland To Fill High Court Seat
- Hospira Urges Fed. Circ. To Keep On-Sale Bar For Patents
- Former J&J Exec Tells Jury Whistleblowing Got Him Fired
- GSK Can't Get Docs On Expert For Reed Smith Atty's Widow
- Hip MDL Plaintiffs' Attys Fight To Expedite Dying Patient's Suit
- Tenn. Hospitals Seek To Erase Some Claims In Meningitis MDL
- Chancery Asked To Dismiss $1.2B Volcano Merger Challenge
- McDermott Adds Arnold & Porter Partner As FDA Group Leader
- Sanofi Underplayed Dangers Of Chemo Drug, Suit Says
- 7th Circ. Kills Wrongful Firing Suit Against Zoetis
- FDA Warning Wire: Stimulants, Data Fraud, Device Lapses
- Deals Rumor Mill: Bashneft, Zoomlion, Ferro Corp.
- White & Case Snags Commercial Litigation Partner From MoFo
- Alere Hit With DOJ Subpoena In FCPA Investigation
- Valeant Stock Rocked Anew By Earnings, Default Warnings
- CDC Proposes Limits For Opioid Painkillers
- Ex-HR Consultant Avoids Prison For Inside Stock Tips
- Updating The Biotechnology Mission For The Bioeconomy
- Jury Awards $2.5M To Polo Horse Owners In Supplement Row
- Wright Medical Wants Bellwether Redo After $11M Verdict
- FDA Panel To Mull Abbott's Breakthrough Dissolving Stent
- PTAB Grants Kyle Bass' Bid To Review Acorda Drug Patents
- FTC Tells 3rd Circ. Wellbutrin Dismissal Misreads Actavis
- The 8 Firms GCs Can't Stop Talking About
- GCs Say These Firms Are Worth Paying Top Dollar For
- Gilead Halts 6 Zydelig Trials After Deaths
- Travelers Must Defend Actavis In Painkiller Suits, Court Told
- Zimmer Picks 2nd Bellwether Suit Over Knee Implants
- Contract Misquoted In 'Pill Mill' Row, 7th Circ. Hears
- GCs Name Most Elite Law Firms
- Deals Rumor Mill: Blackstone, Stemcentrx, Banco Santander
- CVC Capital Acquires Italian Generics Giant Doc Generici
- Q&A With Crowell & Moring's George Ruttinger
- Pfizer Says IRS Owes $8.3M In Interest On Late Refund
- Why Life Sciences Leases Are Not Your Average Transaction
- Group With Hedge Fund Ties Denied Review Of Enbrel Patent
- Pfizer Fights Zoloft MDL Plaintiffs' New Expert Reports
- 3rd Circ. Tosses Case Accusing Hangley Of Repping Fake Co.
- Hedge Fund Offers $10M KaloBios Stake, If Shkreli Benched
- Fresenius Seeks To Ax AIA Review Personally Filed By Bass
- J&J Ducks Motrin Injury Suit Over Man's Suicide
- Drug Co. May Hide Assets Instead Of Hire Attys, Investor Says
- Epstein Becker Nabs King & Spalding Health Partner
- Taxation With Representation: Fenwick, Skadden, Alston
- Senators Call On CMS To Investigate $3B Excess Drug Costs
- Kaye Scholer Partner Resigns In Wake Of Shkreli Indictment
- Medtronic Fights Investors' Appeal In Tainted Study Suit
- 3 Firms To Guide Uptick In Life Sciences IPOs Totaling $200M
- Omnicare Says High Court Ruling Vanquishes Investor Suit
- Travelers, Actavis Square Off Over Painkiller Suit Coverage
- Hedge Funds Can't Access Shares To Satisfy $21M Award
- Biotech Sets $75M IPO Terms While Another Yanks Deal
- Trial Pros: Knobbe Martens' Joseph Re
- Stem Cell Co.'s Trade Secrets Suit Dismissed As Repetitive
- Amarin Settlement Erodes Off-Label Promotion Enforcement
- 2nd Circ. Urged To Toss Pharma Rep.'s Suit Over Prosecution
- DOJ Attys Dish On Pharma, Device Fraud Landscape
- FDA Approves Teva's Generic Viagra Tablets
- Senate Passes Bill To Help Treat, Prevent Opioid Addiction
- PTAB Denies Hedge Fund's Bid For Painkiller Patent Reviews
- CVS Can't Be Held Liable For Doc's Bad Rx, NY Court Rules
- Poor Generic Drug Label Can Be Put On Novartis, Court Says
- IRS Can't Escape $100M Tax Fight Over Mylan Patent Deal
- Sunstein Kann Adds IP Pro From Wolf Greenfield In Boston
- Valeant Settles Suit Over $70M Worth Of 'Surprise' Invoices
- EU OKs Teva's $40B Allergan Buy Pending Cuts In UK, Ireland
- No Deal Too Small For US Antitrust Scrutiny
- Oversize Drug Packaging Suits Are A 'Waste' For Plaintiffs
- FTC Chief Tells Sens. Agency Not Ignoring Drug Price Hikes
- Novo Nordisk Hemophilia Drug Flouts Patent, ITC Judge Says
- Fed Circ. Urged To Invalidate Illumina Sequencing Patent
- SEC Recoups More Gilead Merger Insider Trading Profits
- Yeda Urges Fed. Circ. To Revive Protein Patent Row
- Deals Rumor Mill: Toshiba, Teva, Mediaset
- Most Anti-Bayer Expert Testimony Barred In Mirena IUD Suit
- Sanctions On Ex-Stryker Worker Over Evidence Upheld
- 2 Firms Steer $900M Becton Dickinson-Apax Respiratory JV
- Embattled Valeant Adds 3 Independent Directors To Board
- Recent Limitations On Patent Term Adjustment For 'A' Delay
- The Learned Intermediary Renaissance
- Wealth Management For Mid-Level Partners
- Berkeley Says Rival School Improperly Obtained Gene Patents
- New Medicare Drug Pay Model Invites Industry Clash
- Some Fraud Claims Resurrected In Testosterone MDL
- FDA Warning Wire: Pumps, Clinical Trials, Supplements
- NJ Doc Accused Of Taking Bribes In $100M Referral Scheme
- The Yates Memo: 6 Months Later
- Kyle Bass' Coalition Gets Review Of Cholesterol Drug Patents
- Amarin, FDA Finalize Free Speech Settlement
- J&J Unit Slams Diabetes Drug Blood Disorder Claims
- Diabetes-Focused Senseonics Sets $60M IPO
- Rex Medical Faces Philly Suit Over Vein Filter Injury
- Mylan, Ranbaxy Tell 3rd Circ. To Decertify Provigil Class
- Deals Rumor Mill: Toshiba, Nippon Telegraph, Orange SA
- Sanofi, Merck To End European Joint Vaccine Venture
- Claim Construction Post-Teva: 1st Year Of Fed. Circ. Review
- Fla. Senate Not High On Bill But OKs Medical Pot Revisions
- Omnicare Raises Bar On Exec Opinion Suits In 2nd Circ.
- Takeda, AstraZeneca Say Indian Co. Infringed Daliresp Patent
- Amgen Sues Sandoz Over Biosimilar Patent Talks
- BelHealth Says Geritrex Hid FDA Probe Before $14M Stake Deal
- Md. Hits J&J With Contact Lens Pricing Antitrust Suit
- Fed. Circ. Pushed To Ax Merck Antifungal Infringement Ruling
- PE-Backed Alvogen Bolsters Pipeline With Generics Co. Buy
- Pharma Co. Oversold Dialysis Drug Potential, Suit Claims
- Skin Graft Co. Raps Infringement Verdict At Fed. Circ.
- Deals Rumor Mill: DuPont, Sharp Corp., Americana Group
- 2nd Circ. Says Inyx CEO Still On The Hook For $1M
- Visium Asset Management Under Investigation By DOJ, SEC
- Best Practices For Motions Brief Writing: Part 2
- It's Too Early To Nix Hyland's False Ad Suit, Consumers Say
- 4 Drug Regulations Health Care Providers Must Know
- Judge Defines Scope Of On-Sale Bar Under AIA
- Zoloft MDL Plaintiffs Fight To Keep Expert Reports
- Nordion Settles SEC Case Over Ex-Worker's Russia Bribery
- J&J Fights To Keep Cherokee Risperdal Suit In Federal Court
- Jeffer Mangels Snags Former Alston & Bird IP Partner
- Drug Cos. Say False Claims Suit Hinges On High Court Case
- Franken Introduces Bill To End Tax Breaks For Drug Ads
- USPTO, Others Say Angiomax On-Sale Bar Shouldn't Apply
- Eli Lilly Seeks Sanctions In Contamination Coverage Fight
- Taxation With Representation: Davies, King & Spalding, K&L
- High Court Seeks Lamictal Buyers' Views On Antitrust Appeal
- Sanofi Suits Can't Survive Omnicare Ruling, 2nd Circ. Says
- Best Practices For Motions Brief Writing: Part 1
- Fresenius Requests Stay In Dialysis MDL To Ink Settlement
- Tips For Protecting Hatch-Waxman Stay After Lilly, Alcon
- New Rule 37(e) In Action: Lessons From First 3 Months
- NJ Doctor Escapes Most Claims In Suit Over Spinal Implants
- Insurer Can't Ax Bad-Faith Claim Over Heparin Defense Denial
- Cancer Drug Developer Syndax Prices $53M IPO Below Range
- AbbVie, Others Say Ill. Court Misapplied 7th Circ. Precedent
- 11th Circ. Lets $14M Boston Scientific Royalty Ruling Stand
- Tucker Ellis Snags Ex-Sidley Trial Duo For New Chicago Digs
- Generic Drug Cos. Face Union Action On Price-Fixing Claims
- Judge Skeptical Of Lifting Ex-MedImmune Exec's SEC Ban
- Deals Rumor Mill: Toshiba, Royal Philips, Samsonite
- Most Of Consumer's Expert's Testimony OK'd In J&J Trial
- NY AG Subpoenas Insurers On Hep C Drug Denials
- Trial Pros: White & Case's J. Mark Gidley
- NY AG Fines Endo For Falsely Advertising Opioid Opana ER
- Factors To Consider Before Making Any Patent Moves In Japan
- Trans Ova Fights $6M Verdict In Sex-Selection IP Case
- Major Firms Line Up At High Court To Fight AIA Claim Rules
- Zika Spurs New FDA Blood, Tissue Donation Guidelines
- GSK Asks High Court To Nix Avandia RICO Class Suit
- FTC Scores Patent-Related Docs In AndroGel Row
- GSK Says Generic 'Nasoflow' Infringes 'Flonase' Trademark
- Pfizer Must Face Blind Sales Rep's ADA Suit: 4th Circ.
- Mylan Accused Of 'Whopping Misstatements' In Doryx Row
- AstraZeneca Urges Del. Justices To End Nexium Fraud Case
- Pfizer Can't Escape Narrowed Off-Label Marketing FCA Suit
- Wealth Management For New Law Firm Partners
- McKesson Expands Into Canada With $2.2B Drugstore Buy
- Methods For Asserting Objections Under Amended Rule 34
- 11th Circ. Sinks Challenge To Instruction For Stiefel Fraud Jury
- Accel-KKR Latest To Target Cloud Cos. With IntegriChain Buy
- 2 Helpful Cases On Specific Causation Expert Testimony
- Diet Supplement Co. Owner Admits Using Cheaper Substitutes
- Wis. Justices Deal Policyholders Blow In Defective Part Suits
- One LLP Opens Shop With O'Melveny, Sheppard Mullin Pros
- CEO Rips 'Malicious' Feds After Beating Criminal Case
- Mintz Levin Snags Ex-Kilpatrick Townsend Patent Prosecutor
- Biotech IPOs Nudge 1 Firm Ahead of Peers In Quiet February
- Botched Supplement Killed 21 Polo Horses, Jury Told
- Big Pharma's Animated Ads To Get FDA Scrutiny
- Ex-NVE Exec Presses Bid To DQ Nicoll Davis In Kickback Row
- Pfizer Tells Zoloft MDL Judge Case Fails Without Experts
- FDA Warning Wire: Exoskeletons, Diet Drugs, Salmonella
- Fed. Circ. Asked To Nix PTAB's Power To Start AIA Reviews
- Deals Rumor Mill: Ball Corp., EQT Holdings, SABMiller
- Inclusion Of Bad Ingredient Not Covered, Wis. Justices Say
- Dying Hip Implant Patient Should Stay In MDL, Wright Says
- Olympus To Pay $646M To Settle Kickback, FCPA Probes
- Durbin Asks Abbott To Rethink 'Harsh' IT Worker Layoff Plan
- Key Securities Litigation Issues For Life Science Cos.